Zur Hauptnavigation wechseln Zur Suche wechseln Zum Hauptinhalt wechseln

The role of ultrasound for the personalized botulinum toxin treatment of cervical dystonia

Urban M. Fietzek*, Devavrat Nene, Axel Schramm, Silke Appel-Cresswell, Zuzana Košutzká, Uwe Walter, Jörg Wissel, Steffen Berweck, Sylvain Chouinard, Tobias Bäumer

*Korrespondierende/r Autor/-in für diese Arbeit

Abstract

The visualization of the human body has frequently been groundbreaking in medicine. In the last few years, the use of ultrasound (US) imaging has become a well-established procedure for botulinum toxin therapy in people with cervical dystonia (CD). It is now undisputed among experts that some of the most relevant muscles in this indication can be safely injected under visual US guidance. This review will explore the method from basic technical considerations, current evidence to conceptual developments of the phenomenology of cervical dystonia. We will review the implications of introducing US to our understanding of muscle function and anatomy of common cervical dystonic patterns. We suggest a flow chart for the use of US to achieve a personalized treatment of people with CD. Thus, we hope to contribute a resource that is useful in clinical practice and that stimulates the ongoing development of this valuable technique.

OriginalspracheEnglisch
Aufsatznummer365
ZeitschriftToxins
Jahrgang13
Ausgabenummer5
DOIs
PublikationsstatusVeröffentlicht - 05.2021

Fördermittel

Conflicts of Interest: U.M.F. reports personal fees from Ipsen, Allergan, Merz outside the submitted work; D.N. declares no conflicts of interest; A.S. received speaker honoraria from Allergan, Bayer and Ipsen Pharma as well as consulting fees from Ipsen Pharma not related to the submitted work; S.A.-C. reports speaker honoraria from Allergan and consulting fees and travel reimbursement from Allergan, Merz and Ipsen, outside the submitted work. The Pacific Parkinson’s Research Institute funds the Marg Meikle Professorship which S.A.-C. holds. S.A.-C. serves on the scientific board of the Dystonia Medical Research Foundation Canada; Z.K. reports honoraria from UCB; U.W. has received speaker honoraria and travel reimbursement from Ipsen Pharma, Merz Pharma, Allergan, Bristol-Myers Squibb, Daiichi Sankyo, Bayer Vital, Boehringer Ingelheim and Pfizer, and a research grant from Merz Pharma. He has received royalties from Thieme and Elsevier Press. He serves as editor of the European Journal of Ultrasound; J.W. reports personal fees from Allergan, Ipsen, Merz, Medtronic, Shinogi, outside the submitted work; S.B. reports personal fees from Allergan, Merz, Ipsen outside the submitted work; S.C. has received speaker honoraria, consulting fees and travel reimbursement from Ipsen, Merz and Allergan; T.B. received speaker honoraria and travel reimbursement from Ipsen, Allergan, Merz outside the submitted work.

UN SDGs

Dieser Output leistet einen Beitrag zu folgendem(n) Ziel(en) für nachhaltige Entwicklung

  1. SDG 3 – Gesundheit und Wohlergehen
    SDG 3 – Gesundheit und Wohlergehen
  2. SDG 10 – Weniger Ungleichheiten
    SDG 10 – Weniger Ungleichheiten

Fingerprint

Untersuchen Sie die Forschungsthemen von „The role of ultrasound for the personalized botulinum toxin treatment of cervical dystonia“. Zusammen bilden sie einen einzigartigen Fingerprint.

Zitieren